EUVIMEDEUVIMED entdecken
Open Access

Utilizing Patient Input in Rectal Cancer Trial Design

Janet Alvarez iD, Wini Zambare iD, Manju George, Reese Garcia iD, Phuong Gallagher iD, Caleah Kitchens iD, Aron Bercz, Min Jung Kim iD, Paul B Romesser iD, Andrea Cercek iD, Julio Garcia-Aguilar, Hanna Sanoff iD und 15 weitere

JNCI: Journal of the National Cancer Institute · 2025

DOI: 10.1093/jnci/djaf074 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JNCI: Journal of the National Cancer Institute, 2025. Verfasst von Janet Alvarez und 26 weiteren Autor:innen. Beteiligte Einrichtung: Memorial Sloan Kettering Cancer Center, New York, NY, United States. Hauptthemen laut MEDLINE: Rectal Neoplasms, Research Design, Watchful Waiting, Clinical Trials as Topic. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 19 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: National Cancer Institute Surgical Oncology T32 Research Training, AstraZenenca, National Cancer Institute Cancer Center.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The treatment of locally advanced rectal cancer now includes “watch-and-wait” (WW) management for patients who exhibit a clinical complete response (cCR) to total neoadjuvant therapy (TNT). We assessed patients’ knowledge and preferences regarding WW with the goal of incorporating patient input into clinical trial design.

Methods

Rectal cancer patients in advocacy groups (COLONTOWN/Rectalburgh and Fight CRC) were surveyed regarding perceptions about treatment strategies, tolerable risks of treatment failure, and preferences on clinical trial design. Surveys were initially distributed in 2019, with the shift toward WW prompting re-survey of select questions in 2023.

Results

All respondents preferred enrollment in trials that incorporated patient input. Most respondents (76%) preferred treatment that incorporated chemotherapy escalation over radiation escalation. Furthermore, when presented with a hypothetical patient who developed a cCR after chemoradiation (without the option for WW), 58% of patients chose surgical treatment (with 100% risk of permanent ostomy and 80% chance of cure) over omission of surgery (with <80% chance of cure). In contrast, when the hypothetical patient developed a cCR after TNT (with an option for WW), 82% of patients opted for selective WW over surgery.

Conclusions

This work successfully integrated patient advocacy groups as a resource for obtaining patient input. Surveys revealed patients had a strong preference for chemotherapy escalation, for selective WW when offered, and for incorporation of input into future clinical trial design. These findings describe how well-informed patients approach complex medical decision-making and serve as a starting point for future studies seeking to incorporate patient voices.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Rectal NeoplasmsResearch DesignWatchful WaitingClinical Trials as TopicPatient ParticipationPatient PreferenceHumansFemaleMaleMiddle AgedAgedNeoadjuvant TherapySurveys and QuestionnairesAdult

Autor:innen und Institutionen

  • Memorial Sloan Kettering Cancer Center, New York, NY, United States.
  • COLONTOWN/Paltown Development Foundation, Crownsville, MD, United States.
  • FightCRC Patient Education and Research, Springfield, MO, United States.
  • Division of Oncology, The Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC, United States.
  • Division of Hematology & Oncology, University of Florida, Gainesville, FL, United States.
  • NRG Oncology, Philadelphia, PA, United States.

ORCID-Profile: Janet Alvarez, Wini Zambare, Reese Garcia, Phuong Gallagher, Caleah Kitchens, Min Jung Kim, Paul B Romesser, Andrea Cercek, Hanna Sanoff, Thomas J George, Theodore S Hong, Greg Yothers, Philip A Philip, Olatunji B Alese, Ardaman Shergill, Eileen M O'Reilly, Jeffrey A Meyerhardt, Natally Horvat, Arvind Dasari, Qian Shi, Deborah Schrag, J Joshua Smith

Förderung

  • National Cancer Institute Surgical Oncology T32 Research Training
  • AstraZenenca
  • National Cancer Institute Cancer Center
  • NCI NIH HHS
  • NIH HHS
  • National Cancer Institute Diversity Supplement to "Expansion of Tumoroid Models for Precise Treatment of the Rectal Cancer Patient"
  • Memorial Sloan Kettering Cancer Center's core resources
  • Memorial Sloan Kettering Cancer Center’s core resources

Zitieren

APA

Alvarez, J., Zambare, W., George, M., Garcia, R., Gallagher, P., Kitchens, C., Bercz, A., Kim, M. J., Romesser, P. B., Cercek, A., Garcia-Aguilar, J., Sanoff, H., George, T. J., Hong, T. S., Yothers, G., Philip, P. A., Al Baghdadi, T., Alese, O. B., Shergill, A., …, & Smith, J. J. (2025). Utilizing Patient Input in Rectal Cancer Trial Design. JNCI: Journal of the National Cancer Institute. https://doi.org/10.1093/jnci/djaf074

Vancouver

Alvarez J, Zambare W, George M, Garcia R, Gallagher P, Kitchens C, et al. Utilizing Patient Input in Rectal Cancer Trial Design. JNCI: Journal of the National Cancer Institute. 2025. doi:10.1093/jnci/djaf074

BibTeX
@article{Alvarez2025,
  author = {Alvarez, Janet and Zambare, Wini and George, Manju and Garcia, Reese and Gallagher, Phuong and Kitchens, Caleah and Bercz, Aron and Kim, Min Jung and Romesser, Paul B and Cercek, Andrea and Garcia-Aguilar, Julio and Sanoff, Hanna and George, Thomas J and Hong, Theodore S and Yothers, Greg and Philip, Philip A and Al Baghdadi, Tareq and Alese, Olatunji B and Shergill, Ardaman and O'Reilly, Eileen M and Meyerhardt, Jeffrey A and Horvat, Natally and Dasari, Arvind and Hall, William A and Shi, Qian and Schrag, Deborah and Smith, J Joshua},
  title = {Utilizing Patient Input in Rectal Cancer Trial Design},
  journal = {JNCI: Journal of the National Cancer Institute},
  year = {2025},
  doi = {10.1093/jnci/djaf074}
}
Kostenlos starten →